423 related articles for article (PubMed ID: 38725663)
1. Effect of gut hormones on bone metabolism and their possible mechanisms in the treatment of osteoporosis.
Liu H; Xiao H; Lin S; Zhou H; Cheng Y; Xie B; Xu D
Front Pharmacol; 2024; 15():1372399. PubMed ID: 38725663
[TBL] [Abstract][Full Text] [Related]
2. Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment.
Schiellerup SP; Skov-Jeppesen K; Windeløv JA; Svane MS; Holst JJ; Hartmann B; Rosenkilde MM
Front Endocrinol (Lausanne); 2019; 10():75. PubMed ID: 30863364
[TBL] [Abstract][Full Text] [Related]
3. Associations between Postprandial Gut Hormones and Markers of Bone Remodeling.
Jensen NW; Clemmensen KKB; Jensen MM; Pedersen H; Færch K; Diaz LJ; Quist JS; Størling J
Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579074
[TBL] [Abstract][Full Text] [Related]
4. GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment.
Gabe MBN; Skov-Jeppesen K; Gasbjerg LS; Schiellerup SP; Martinussen C; Gadgaard S; Boer GA; Oeke J; Torz LJ; Veedfald S; Svane MS; Bojsen-Møller KN; Madsbad S; Holst JJ; Hartmann B; Rosenkilde MM
Pharmacol Res; 2022 Feb; 176():106058. PubMed ID: 34995796
[TBL] [Abstract][Full Text] [Related]
5. Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats.
Baldassano S; Gasbjerg LS; Kizilkaya HS; Rosenkilde MM; Holst JJ; Hartmann B
Front Endocrinol (Lausanne); 2019; 10():492. PubMed ID: 31447774
[TBL] [Abstract][Full Text] [Related]
6. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
[TBL] [Abstract][Full Text] [Related]
7. The Gut-Bone Axis in Diabetes.
Maagensen H; Helsted MM; Gasbjerg LS; Vilsbøll T; Knop FK
Curr Osteoporos Rep; 2023 Feb; 21(1):21-31. PubMed ID: 36441432
[TBL] [Abstract][Full Text] [Related]
8. Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism.
Hansen MSS; Tencerova M; Frølich J; Kassem M; Frost M
Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):25-37. PubMed ID: 28722834
[TBL] [Abstract][Full Text] [Related]
9. Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males.
Zilstorff DB; Richter MM; Hannibal J; Jørgensen HL; Sennels HP; Wewer Albrechtsen NJ
BMC Endocr Disord; 2024 Mar; 24(1):38. PubMed ID: 38481208
[TBL] [Abstract][Full Text] [Related]
10. The role of endogenous GIP and GLP-1 in postprandial bone homeostasis.
Helsted MM; Gasbjerg LS; Lanng AR; Bergmann NC; Stensen S; Hartmann B; Christensen MB; Holst JJ; Vilsbøll T; Rosenkilde MM; Knop FK
Bone; 2020 Nov; 140():115553. PubMed ID: 32730920
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women: A preliminary study.
Skov-Jeppesen K; Veedfald S; Madsbad S; Holst JJ; Rosenkilde MM; Hartmann B
Bone; 2021 Nov; 152():116065. PubMed ID: 34153529
[TBL] [Abstract][Full Text] [Related]
12. The Antiresorptive Effect of GIP, But Not GLP-2, Is Preserved in Patients With Hypoparathyroidism-A Randomized Crossover Study.
Skov-Jeppesen K; Hepp N; Oeke J; Hansen MS; Jafari A; Svane MS; Balenga N; Olson JA; Frost M; Kassem M; Madsbad S; Beck Jensen JE; Holst JJ; Rosenkilde MM; Hartmann B
J Bone Miner Res; 2021 Aug; 36(8):1448-1458. PubMed ID: 33852173
[TBL] [Abstract][Full Text] [Related]
13. Receptors and effects of gut hormones in three osteoblastic cell lines.
Pacheco-Pantoja EL; Ranganath LR; Gallagher JA; Wilson PJ; Fraser WD
BMC Physiol; 2011 Jul; 11():12. PubMed ID: 21801348
[TBL] [Abstract][Full Text] [Related]
14. GIP and GLP-1, the two incretin hormones: Similarities and differences.
Seino Y; Fukushima M; Yabe D
J Diabetes Investig; 2010 Apr; 1(1-2):8-23. PubMed ID: 24843404
[TBL] [Abstract][Full Text] [Related]
15. GLP-1 receptor agonism and GIP receptor antagonism induce substantial alterations in enteroendocrine and islet cell populations in obese high fat fed mice.
Sridhar A; Khan D; Flatt PR; Moffett CR; Irwin N
Peptides; 2023 Nov; 169():171093. PubMed ID: 37660881
[TBL] [Abstract][Full Text] [Related]
16. Is the Secret in the Gut? SuperJump Activity Improves Bone Remodeling and Glucose Homeostasis by GLP-1 and GIP Peptides in Eumenorrheic Women.
Vasto S; Amato A; Proia P; Baldassano S
Biology (Basel); 2022 Feb; 11(2):. PubMed ID: 35205162
[TBL] [Abstract][Full Text] [Related]
17. Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach.
Batiha GE; Al-Kuraishy HM; Al-Gareeb AI; Ashour NA; Negm WA
Inflammopharmacology; 2023 Aug; 31(4):1683-1693. PubMed ID: 37208555
[TBL] [Abstract][Full Text] [Related]
18. Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice.
Akindehin S; Liskiewicz A; Liskiewicz D; Bernecker M; Garcia-Caceres C; Drucker DJ; Finan B; Grandl G; Gutgesell R; Hofmann SM; Khalil A; Liu X; Cota P; Bakhti M; Czarnecki O; Bastidas-Ponce A; Lickert H; Kang L; Maity G; Novikoff A; Parlee S; Pathak E; Schriever SC; Sterr M; Ussar S; Zhang Q; DiMarchi R; Tschöp MH; Pfluger PT; Douros JD; Müller TD
Mol Metab; 2024 May; 83():101915. PubMed ID: 38492844
[TBL] [Abstract][Full Text] [Related]
19. Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes.
Bergmann NC; Lund A; Gasbjerg LS; Jørgensen NR; Jessen L; Hartmann B; Holst JJ; Christensen MB; Vilsbøll T; Knop FK
J Clin Endocrinol Metab; 2019 Jul; 104(7):2953-2960. PubMed ID: 30848791
[TBL] [Abstract][Full Text] [Related]
20. Regulation of glucagon-like peptide-1-(7-36) amide, peptide YY, and neurotensin secretion by neurotransmitters and gut hormones in the isolated vascularly perfused rat ileum.
Dumoulin V; Dakka T; Plaisancie P; Chayvialle JA; Cuber JC
Endocrinology; 1995 Nov; 136(11):5182-8. PubMed ID: 7588257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
